 The FDAs Advisory Committee has unanimously backed Bluebird bio Incs NASDAQ: BLUE gene therapy for a rare blood disorder. The panel of 13 voted unanimously for betibeglogene autotemcel beti-cel as a one-time gene therapy to treat Beta-thalassemia patients dependent on. 